/

Società

An

Non verificato

Anthos Therapeutics, Inc.

Di cosa scriviamo

CardiologiaEventiFarmaceuticaIndustriaSalute

1 comunicati stampa

Guarda tutti i comunicati

02/09/2024

Salute

Medicina - Varie

Scienza

Farmaceutica

Cardiologia

Eventi

Industria

Anthos Therapeutics Unveils Additional Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating that the Factor XI Inhibitor Abelacimab was Associated with Remarkably Low Levels of Periprocedural Bleeding in Patients with Atrial Fibrillation

Fonte

Anthos Therapeutics, Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0